Author

Irene Paassen

Oncode InstituteORCID 0009-0000-7737-3292Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

Jarno DrostiD· 2 shared Alden King-Yung LeungiD· 1 shared Alina NaveediD· 1 shared Andrej BenjakiD· 1 shared Annelisa M. CorneliD· 1 shared Baojie ZhangiD· 1 shared Bart VandekerckhoveiD· 1 shared Bence DánieliD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jarno DrostORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 11, 2026

BAF complexes cooperate with lineage-restricted transcription factors to establish cell-state-specific regulatory programs

Jiayou He, Carla Rios Arceo, Nadia Anderson…·Jarno Drost

The paper shows that SMARCB1 loss disrupts TF-dependent chromatin priming, revealing lineage-specific regulatory output of BAF complexes is constrained by TF repertoire in ATRT tumors.

DOI 10.64898/2026.11.08.764927

humanChIP-seq

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedOct 31, 2026

Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as potential CAR T cell target for pediatric solid tumors.

Juliane L. Buhl, Jannet Koelewijn, Charlotte op ’t Hoog…·Claudia Y. Janda

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedJan 14, 2026

A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules

Phillip Thienger, Irene Paassen, Xiaosai Yao…·Mark A. Rubin

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

11 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky